Dermatología Estado actual de terapias CRISPR: nueva esperanza en elarmamento dermatológico
Referencias bibliográficas
Devi V, Harjai K,
Chhibber S. CRISPR-Cas systems: role in cellular processes beyond adaptive
immunity. Folia Microbiol. 2022; 67: 837–50.
Huang J, Zhou Y, Li J,
Lu A, Liang C. CRISPR/Cas systems: Delivery and application in gene therapy. Front Bioeng Biotechnol. 2022;
10: 942325.
Ain QU, Campos EVR,
Huynh A, Witzigmann D, Hedtrich S. Gene Delivery to the Skin – How Far Have We
Come?. Trends Biotechnol. 2021; 39: 474–87.
De Rosa L, Latella MC,
Secone Seconetti A, et al. Toward Combined Cell and Gene Therapy for
Genodermatoses.Cold Spring Harb Perspect Biol. 2020; 12: 035667.
Bhat P, Garibyan L. The
Potential of CRISPR-Guided Therapies in the Dermatology Clinic. JID Innov.
2022; 2: 100103.
Bonafont J, Mencía Á,
García M, Torres R, Rodríguez S, Carretero M, et al. Clinically Relevant Correction of Recessive Dystrophic
Epidermolysis Bullosa by Dual sgRNA CRISPR/Cas9-Mediated
Gene Editing. Mol Ther. 2019; 27: 986–98.
Wu W, Lu Z, Li F, Wang
W, Qian N, Duan J, et al.
Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of
recessive dystrophic epidermolysis bullosa mouse model. Proc Natl Acad Sci U S
A. 2017; 114: 1660–1665.
Izmiryan A, Ganier C,
Bovolenta M, Schmitt A, Mavilio F, Hovnanian A. Ex Vivo COL7A1 Correction for
Recessive Dystrophic Epidermolysis Bullosa Using CRISPR/Cas9 and
Homology-Directed Repair. Mol Ther Nucleic Acids. 2018; 12: 554–67.
Tsai YC, Tsai TF.
Overlapping Features of Psoriasis and Atopic Dermatitis: From Genetics to
Immunopathogenesis to Phenotypes.Int J Mol Sci. 2022; 23: 5518.
Capon F. The Genetic
Basis of Psoriasis.Int J Mol Sci. 2017; 18: 2526.
Mahil SK, Catapano M,
Di Meglio P, Dand N, Ahlfors H, Carr IM, et al.
An analysis of IL-36 signature genes and individuals with IL1RL2
knockout mutations validates IL-36 as a psoriasis therapeutic target. Sci
Transl Med. 2017; 9: 2514.
Al-Shobaili HA,
Ahmed AA, Alnomair N, Alobead ZA, Rasheed Z. Molecular Genetic of Atopic
dermatitis: An Update.Int J Health Sci (Qassim). 2016; 10: 96-120.
Moosbrugger-Martinz V,
Leprince C, Méchin MC, Simon
M, Blunder S, Gruber R, et al.
Revisiting the Roles of Filaggrin in Atopic Dermatitis.Int J Mol Sci. 2022; 23:
5318.
Kezic S, O’Regan GM,
Lutter R, Jakasa I, Koster ES, Saunders S, et al.
Filaggrin loss-offunction mutations are associated with enhanced expression of
IL-1 cytokines in the stratum corneum of patients with atopic dermatitis and in
a murine model of filaggrin deficiency. J Allergy Clin Immunol. 2012; 129:
1031-1039.
Primiano MJ, Lefker BA,
Bowman MR, Bree AG, Hubeau C, Bonin PD, et al.
Efficacy and Pharmacology of the NLRP3 Inflammasome Inhibitor CP-456,773
(CRID3) in Murine Models of Dermal and Pulmonary Inflammation. J Immunol. 2016;
197: 2421–2433.
Wan T, Pan Q, Ping Y.
Microneedle-assisted genome editing: A transdermal strategy of targetingNLRP3by CRISPR-Cas9 for synergistic
therapy of inflammatory skin disorders.Sci Adv. 2021; 7: 2888.
Lam KN,
Spanogiannopoulos P, Soto-Perez P, Alexander M, Nalley MJ, Bisanz JE, et al. Phage-delivered CRISPR-Cas9
for strain-specific depletion and genomic deletions in the gut microbiome. Cell
Rep. 2021; 37: 109930.
Selle K, Fletcher JR,
Tuson H, Schmitt DS, McMillan L, Vridhambal GS, et al.In VivoTargeting of Clostridioides difficile Using
Phage-Delivered CRISPR-Cas3 Antimicrobials.mBio. 2020; 11: 00019-20.
Alkilani AZ, McCrudden
MT, Donnelly RF. Transdermal Drug Delivery: Innovative Pharmaceutical
Developments Based on Disruption of the Barrier Properties of the stratum
corneum.Pharmaceutics. 2015; 7: 438-470.
NOTA:Toda la información que se brinda en este artículo es de carácter investigativo y con fines académicos y de actualización para estudiantes y profesionales de la salud. En ningún caso es de carácter general ni sustituye el asesoramiento de un médico. Ante cualquier duda que pueda tener sobre su estado de salud, consulte con su médico o especialista.
Instituto de Medicina Tropical - Facultad de Medicina - Universidad Central de Venezuela.
Elaborado por el Centro de Análisis de Imágenes Biomédicas Computarizadas CAIBCO, caibco@ucv.ve
Este portal ha sido desarrollado gracias al apoyo del Fonacit
